Theriva Biologics, Inc. (TOVX) VIRAGE Phase 2b Results Published; VIRAGE2 Underway

Theriva Biologics said VIRAGE Phase 2b data for VCN-01 in metastatic pancreatic cancer were published in Nature Medicine, showing improved OS, PFS and DoR vs SoC. The company has initiated VIRAGE2 to assess more frequent dosing; initial data are anticipated by Q3 2027.Material DetailsContext by AI…